×
About 955 results

ALLMedicine™ Blastic Plasmacytoid Dendritic Cell Center

Research & Reviews  449 results

Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic ...
https://doi.org/10.1016/j.clml.2021.02.008
Clinical Lymphoma, Myeloma & Leukemia; Wang SY, Thomassen K et. al.

Apr 2nd, 2021 - Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.|2021|Wang SY,Thomassen K,Kurch L,Opitz S,Franke GN,|

Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Ce...
https://doi.org/10.1188/21.CJON.E10-E16
Clinical Journal of Oncology Nursing; Morin A, Kechedjian F et. al.

Mar 19th, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive, and often fatal hematologic malignancy. BPDCN is not a new entity, but it has been renamed and reclassified, which, in part, contributes to it being underrecogn...

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948279
Blood Advances; Renosi F, Roggy A et. al.

Mar 9th, 2021 - Oncogenesis and ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) remain uncertain, between canonical plasmacytoid dendritic cells (pDCs) and AXL+ SIGLEC6+ DCs (AS-DCs). We compared 12 BPDCN to 164 acute leukemia by Affymetrix HG-U1...

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigene...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871073
The Journal of International Medical Research; Dang X, Zhou D et. al.

Feb 3rd, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematodermic malignancy derived from plasmacytoid dendritic cell precursors. Despite advances in our understanding of tumor cell surface markers, the pathogenesis of BPDCN ...

see more →

Guidelines  1 results

ELZONRIS (tagraxofusp-erzs) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf

ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. Administer ELZONRIS at 12 mcg/kg intravenously over 15 minutes once daily on da...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  471 results

Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic ...
https://doi.org/10.1016/j.clml.2021.02.008
Clinical Lymphoma, Myeloma & Leukemia; Wang SY, Thomassen K et. al.

Apr 2nd, 2021 - Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.|2021|Wang SY,Thomassen K,Kurch L,Opitz S,Franke GN,|

Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Ce...
https://doi.org/10.1188/21.CJON.E10-E16
Clinical Journal of Oncology Nursing; Morin A, Kechedjian F et. al.

Mar 19th, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive, and often fatal hematologic malignancy. BPDCN is not a new entity, but it has been renamed and reclassified, which, in part, contributes to it being underrecogn...

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948279
Blood Advances; Renosi F, Roggy A et. al.

Mar 9th, 2021 - Oncogenesis and ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) remain uncertain, between canonical plasmacytoid dendritic cells (pDCs) and AXL+ SIGLEC6+ DCs (AS-DCs). We compared 12 BPDCN to 164 acute leukemia by Affymetrix HG-U1...

Fast Five Quiz: Blastic Plasmacytoid Dendritic Cell Neoplasm Presentation and Diagnosis
https://reference.medscape.com/viewarticle/944308

Feb 22nd, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a malignancy derived from plasmacytoid dendritic cells. It is a clinically aggressive hematologic cancer with a proclivity for the skin and leukemic involvement, which is difficult to diagnos...

see more →

News  31 results

Fast Five Quiz: Blastic Plasmacytoid Dendritic Cell Neoplasm Presentation and Diagnosis
https://reference.medscape.com/viewarticle/944308

Feb 22nd, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a malignancy derived from plasmacytoid dendritic cells. It is a clinically aggressive hematologic cancer with a proclivity for the skin and leukemic involvement, which is difficult to diagnos...

Tagraxofusp produces high response rate in BPDCN
https://www.mdedge.com/hematology-oncology/article/199516/leukemia-myelodysplasia-transplantation/tagraxofusp-produces-high?channel=39313
Jennifer Smith

Apr 24th, 2019 - Tagraxofusp demonstrated efficacy in a phase 2 trial of patients with previously treated or untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN). The overall response rate was 90% in previously untreated patients who received the highest.

FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm
https://www.mdedge.com/hematology-oncology/article/191723/rare-diseases/fda-approves-elzonris-blastic-plasmacytoid
Laura Nikolaides

Dec 21st, 2018 - The Food and Drug Administration has approved tagraxofusp-erzs (Elzonris) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients, 2 years of age and older. Approval was based on efficacy.

FDA OKs New Options for Two Rare Blood Diseases
https://www.medpagetoday.com/hematologyoncology/hematology/77084

Dec 21st, 2018 - WASHINGTON -- The FDA announced new approvals for two rare and life-threatening blood diseases on Friday, as blastic plasmacytoid dendritic cell neoplasm (BPDCN) gets its first approved agent and paroxysmal nocturnal hemoglobinuria (PNH) gets a ne...

see more →